Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Adv Sci (Weinh) ; 9(14): e2104333, 2022 05.
Article in English | MEDLINE | ID: covidwho-1782562

ABSTRACT

Coronavirus disease 2019 (COVID-19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID-19 hyperimmune globulin (COVID-HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP-CorV (Sinopharm COVID-19 vaccine). COVID-HIG shows high-affinity binding to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, the receptor-binding domain (RBD), the N-terminal domain of the S protein, and the nucleocapsid protein; and blocks RBD binding to human angiotensin-converting enzyme 2 (hACE2). Pseudotyped and authentic virus-based assays show that COVID-HIG displays broad-spectrum neutralization effects on a wide variety of SARS-CoV-2 variants, including D614G, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529) in vitro. However, a significant reduction in the neutralization titer is detected against Beta, Delta, and Omicron variants. Additionally, assessments of the prophylactic and treatment efficacy of COVID-HIG in an Adv5-hACE2-transduced IFNAR-/- mouse model of SARS-CoV-2 infection show significantly reduced weight loss, lung viral loads, and lung pathological injury. Moreover, COVID-HIG exhibits neutralization potency similar to that of anti-SARS-CoV-2 hyperimmune globulin from pooled convalescent plasma. Overall, the results demonstrate the potential of COVID-HIG against SARS-CoV-2 infection and provide reference for subsequent clinical trials.


Subject(s)
COVID-19 Vaccines , COVID-19 , Globulins , Animals , COVID-19/therapy , Globulins/therapeutic use , Humans , Immunization, Passive , Mice , SARS-CoV-2 , Spike Glycoprotein, Coronavirus
2.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-310890

ABSTRACT

Background: COVID-19 outbreak in Wuhan, China recently. It quickly spread throughout worldwide. In this study, we systematically reviewed the clinical features and outcomes of pregnant women with COVID-19. Methods: : PubMed、Web of Science、EMBASE、MEDLINE were searched from January 1, 2020 to April 16, 2020. Case review of pregnant women infected with COVID-19 were included. Two reviewers screened 366 literatures and 14 studies included, four reviewers independently extracted the features of the literatures. We used random-effects model to analyze incidence (P) and 95% confidence interval (95%CI). Heterogeneity was assessed using the I 2 statistic. Results: : The meta- analysis included 236 pregnant women with COVID-19. The results were as follows: positive CT findings (71%;95%CI, 0.49~0.93), cesarean section (65%;95%CI, 0.42~0.87), fever (51%;95%CI, 0.35~0.67), lymphopenia (49%;95%CI, 0.29~0.70), coexisting disorders (33%;95%CI, 0.21~0.44), cough (31%;95%CI, 0.23~0.39), fetal distress (29%;95%CI, 0.08~0.49), preterm labor (23%;95%CI, 0.14~0.32), severe case or death (12%;95%CI, 0.03~0.20). The subgroup analysis showed compared with nonpregnant patients, pregnant women with COVID-19 had significantly lower incidences of fever (pregnant women group, 51%;nonpregnant patients group, 91%;P<0.00001) and cough (pregnant women group, 31%;nonpregnant patients group, 67%;P<0.0001). Conclusions: : The incidence of fever, cough and positive CT findings in pregnant women with COVID-19 is less than that in the general population, preterm labor is the opposite. There is no evidence that COVID-19 can propagate vertically for the time being.

3.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-325074

ABSTRACT

Background: COVID-19 has become a global pandemic. Its occurrence has substantially affected the psychological condition of pregnant women. The purpose of this study is to learn about the incidence of anxiety and depression among pregnant women during the pandemic, and to conduct a meta-analysis of the existing research. Methods: PubMed, Web of Science and EMBASE were searched without a lower time limit and up to August 13, 2020. The incidences of anxiety and depression among pregnant women were synthesized and discussed. Results: The prevalence of anxiety in 8 studies with a total sample size of 7493 individuals was 43% (95% confidence interval: 0.28-0.58), and the prevalence of depression in 7 studies with a sample size of 6116 people was 32% (95% confidence interval: 0.26-0.37). Significant heterogeneity was detected across studies of these incidence estimates. Subgroup analysis included the economic status to explore the sources of heterogeneity, and Egger’s test was conducted to examine the publication bias. Conclusions: Since significant heterogeneity has been detected in studies of anxiety and depression, we must interpret the results with caution. As the COVID-19 pandemic will not end in a short time, corresponding psychological interventions must be implemented to address the mental health of pregnant women.

4.
J Thorac Dis ; 13(12): 6866-6875, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1623786

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic is still raging worldwide. Efficient, fast and low-cost severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid detection methods are urgently needed. METHODS: A rapid PCR temperature change mode was explored by moving the reaction tube between the independent temperature modules with large temperature differences and a portable ultra-fast real-time PCR instrument were developed. We established a rapid SARS-CoV-2 test method using the ultra-fast real-time PCR instrument, a China Food and Drug Administration-certified SARS-CoV-2 reagent and optimized reaction condition. The analytical and clinical performances of the rapid tests were evaluated by comparing with the standard SARS-CoV-2 tests. RESULTS: The new temperature change mode can effectively shorten the amplification reaction time and be successfully used in the development of the ultra-fast real-time PCR instrument. The rapid SARS-CoV-2 test method was established and the time to yield results were greatly shortened from 81 min of the standard test to 31 min. Specificity of the rapid test was assessed and no non-specific amplification (0/63) was observed. The limits of detection of the rapid and standard tests were similar. Clinical performance was evaluated using 184 respiratory specimens from patients with suspected SARS-CoV-2 infection. The positive agreement between the rapid and standard tests was 100% (67/67), the negative agreement was 97.4% (114/117), and the kappa statistic was 0.965 (P<0.001). No significant differences in the Ct values for each target gene were observed between the rapid test and the standard test (P>0.05). CONCLUSIONS: We had developed a 30-minute detection method for SARS-CoV-2 nucleic acid using a novel ultra-fast real-time PCR instrument. The rapid test method may impact on patient management.

5.
Emerg Microbes Infect ; 11(1): 168-171, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1623181

ABSTRACT

HCoV-OC43 is one of the mildly pathogenic coronaviruses with high infection rates in common population. Here, 43 HCoV-OC43 related cases with pneumonia were reported, corresponding genomes of HCoV-OC43 were obtained. Phylogenetic analyses based on complete genome, orf1ab and spike genes revealed that two novel genotypes of HCoV-OC43 have emerged in China. Obvious recombinant events also can be detected in the analysis of the evolutionary dynamics of novel HCoV-OC43 genotypes. Estimated divergence time analysis indicated that the two novel genotypes had apparently independent evolutionary routes. Efforts should be conducted for further investigation of genomic diversity and evolution analysis of mildly pathogenic coronaviruses.


Subject(s)
Common Cold/epidemiology , Coronavirus Infections/epidemiology , Coronavirus OC43, Human/genetics , Genome, Viral , Genotype , Pneumonia, Viral/epidemiology , Base Sequence , Bayes Theorem , Child , Child, Hospitalized , Child, Preschool , China/epidemiology , Common Cold/pathology , Common Cold/transmission , Common Cold/virology , Coronavirus Infections/pathology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Coronavirus OC43, Human/classification , Coronavirus OC43, Human/pathogenicity , Epidemiological Monitoring , Female , Humans , Infant , Male , Monte Carlo Method , Mutation , Phylogeny , Pneumonia, Viral/pathology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , Recombination, Genetic
6.
Disease Surveillance ; 36(6):587-592, 2021.
Article in Chinese | CAB Abstracts | ID: covidwho-1395020

ABSTRACT

Objective: To understand the epidemiological characteristics of imported coronavirus disease 2019 (COVID-19) cases detected in Chengdu, Sichuan, and provide scientific basis for the prevention and control of COVID-19.

9.
Nat Commun ; 12(1): 4144, 2021 07 06.
Article in English | MEDLINE | ID: covidwho-1298839

ABSTRACT

To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Immunoglobulin G/blood , Receptors, Virus/immunology , SARS-CoV-2/immunology , Adult , Animals , Blood Donors , COVID-19/therapy , Cell Line , China , Chlorocebus aethiops , Convalescence , Female , Humans , Immunity, Humoral/immunology , Immunization, Passive , Immunologic Memory/immunology , Longitudinal Studies , Male , Sex Factors , Spike Glycoprotein, Coronavirus/immunology , Vero Cells
10.
Chin Med ; 16(1): 44, 2021 Jun 07.
Article in English | MEDLINE | ID: covidwho-1261276

ABSTRACT

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), first broke out in Wuhan, China, in 2019. SARS-CoV-2 develops many types of mutations (such as B.1.1.7), making diagnosis and treatment challenging. Although we now have a preliminary understanding of COVID-19, including pathological changes, clinical manifestations, and treatment measures, we also face new difficulties. The biggest problem is that most COVID-19 patients might face sequelae (e.g., fatigue, sleep disturbance, pulmonary fibrosis) during the recovery phase. We aimed to test six Chinese patent medicines to treat three major abnormal symptoms in COVID-19 patients during the recovery phase, including cardiopulmonary function, sleep disturbance, and digestive function. We launched the "three syndromes and six Chinese patent medicines" randomized, double-blind, placebo-controlled, multicenter clinical trial on April 10, 2020. The results showed that Jinshuibao tablets and Shengmaiyin oral liquid significantly improved the cardiopulmonary function of recovering COVID-19 patients. Shumian capsules, but not Xiaoyao capsules, significantly improved patients' sleep disorders. This might be because the indication of Xiaoyao capsules is liver qi stagnation rather than psychological or emotional problems. Xiangsha Liujun pills and Ludangshen oral liquid significantly improved digestive function. Our research provides a guideline for treating COVID-19 sequelae in patients during the recovery period based on high-quality evidence.

11.
Virus Res ; 300: 198445, 2021 07 15.
Article in English | MEDLINE | ID: covidwho-1213559

ABSTRACT

The emergency SARS-CoV-2, a member of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV), is still greatly harming the health of mankind. SARS-CoV-2-specific monoclonal antibodies (MAbs), which can identify SARS-CoV-2 from common human coronaviruses, are considered to extensively apply to developing rapid and reliable antigen assays. In this study we generated a rabbit MAb (RAb) detecting SARS-CoV-2 nucleocapsid protein (NP), which has cross-reaction with SARS-CoV-1 NP, but not with NPs of MERS and common human CoVs (OC43, NL63, 229E, and HKU1). With truncated NP fragments and synthesized peptides, the linear epitope detected by RAb was mapped in peptide N4-8, 393-407 amino acid residue (TLLPAADLDDFSKQL) of SARS-CoV-2 NP. This epitope N4-8 was highly conserved in SARSr-CoVs, including SARS-CoV-2, SARS-CoV-1, and bat CoV RaTG13 strain. However, the corresponding peptide of bat SARSr-CoV BtKY72 strain could not be recognized by RAb, which indicates amino acid D399 may be critical for N4-8 epitope detected by RAb. The present study will be conducive to developing reliable diagnosis for SARS-CoV-2 and gaining insights into the function of the SARS-CoV-2 N protein.


Subject(s)
Antibodies, Monoclonal/immunology , COVID-19 Serological Testing/methods , COVID-19/diagnosis , Coronavirus Nucleocapsid Proteins/immunology , SARS-CoV-2 , Epitope Mapping , Humans , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Sensitivity and Specificity
14.
Nat Commun ; 11(1): 3543, 2020 07 15.
Article in English | MEDLINE | ID: covidwho-974925

ABSTRACT

The sudden deterioration of patients with novel coronavirus disease 2019 (COVID-19) into critical illness is of major concern. It is imperative to identify these patients early. We show that a deep learning-based survival model can predict the risk of COVID-19 patients developing critical illness based on clinical characteristics at admission. We develop this model using a cohort of 1590 patients from 575 medical centers, with internal validation performance of concordance index 0.894 We further validate the model on three separate cohorts from Wuhan, Hubei and Guangdong provinces consisting of 1393 patients with concordance indexes of 0.890, 0.852 and 0.967 respectively. This model is used to create an online calculation tool designed for patient triage at admission to identify patients at risk of severe illness, ensuring that patients at greatest risk of severe illness receive appropriate care as early as possible and allow for effective allocation of health resources.


Subject(s)
Coronavirus Infections/diagnosis , Coronavirus Infections/pathology , Deep Learning/statistics & numerical data , Pneumonia, Viral/diagnosis , Pneumonia, Viral/pathology , Triage/methods , Betacoronavirus , COVID-19 , Critical Illness , Hospitalization , Humans , Middle Aged , Models, Theoretical , Pandemics , Prognosis , Risk , SARS-CoV-2 , Survival Analysis
15.
Microbiol Resour Announc ; 9(8)2020 Feb 20.
Article in English | MEDLINE | ID: covidwho-833422

ABSTRACT

We report the complete genome sequences of five human coronavirus NL63 (HCoV-NL63) strains obtained using next-generation sequencing. The five HCoV-NL63 strains were obtained from hospitalized children with severe acute respiratory infection detected in Guangdong, China. This study provides several complete genomes of HCoV-NL63 and improves our understanding of HCoV-NL63 evolution in China.

16.
Emerg Microbes Infect ; 9(1): 246-255, 2020.
Article in English | MEDLINE | ID: covidwho-774889

ABSTRACT

Human coronavirus NL63 (HCoV-NL63) is primarily associated with common cold in children, elderly and immunocompromised individuals. Outbreaks caused by HCoV-NL63 are rare. Here we report a cluster of HCoV-NL63 cases with severe lower respiratory tract infection that arose in Guangzhou, China, in 2018. Twenty-three hospitalized children were confirmed to be HCoV-NL63 positive, and most of whom were hospitalized with severe pneumonia or acute bronchitis. Whole genomes of HCoV-NL63 were obtained using next-generation sequencing. Phylogenetic and single amino acid polymorphism analyses showed that this outbreak was associated with two subgenotypes (C3 and B) of HCoV-NL63. Half of patients were identified to be related to a new subgenotype C3. One unique amino acid mutation at I507 L in spike protein receptor binding domain (RBD) was detected, which segregated this subgenotype C3 from other known subgenotypes. Pseudotyped virus bearing the I507 L mutation in RBD showed enhanced entry into host cells as compared to the prototype virus. This study proved that HCoV-NL63 was undergoing continuous mutation and has the potential to cause severe lower respiratory disease in humans.


Subject(s)
Coronavirus Infections , Coronavirus NL63, Human/genetics , Respiratory Tract Infections/virology , Child, Preschool , China , Coronavirus NL63, Human/isolation & purification , Genotype , Humans , Infant , Phylogeny
17.
BMC Infect Dis ; 20(1): 564, 2020 Aug 03.
Article in English | MEDLINE | ID: covidwho-705301

ABSTRACT

BACKGROUND: The recent COVID-19 outbreak in Wuhan, China, has quickly spread throughout the world. In this study, we systematically reviewed the clinical features and outcomes of pregnant women with COVID-19. METHODS: PubMed, Web of Science, EMBASE and MEDLINE were searched from January 1, 2020, to April 16, 2020. Case reports and case series of pregnant women infected with SARS-CoV-2 were included. Two reviewers screened 366 studies and 14 studies were included. Four reviewers independently extracted the features from the studies. We used a random-effects model to analyse the incidence (P) and 95% confidence interval (95% CI). Heterogeneity was assessed using the I2 statistic. RESULTS: The meta-analysis included 236 pregnant women with COVID-19. The results were as follows: positive CT findings (71%; 95% CI, 0.49-0.93), caesarean section (65%; 95% CI, 0.42-0.87), fever (51%; 95% CI, 0.35-0.67), lymphopenia (49%; 95% CI, 0.29-0.70), coexisting disorders (33%; 95% CI, 0.21-0.44), cough (31%; 95% CI, 0.23-0.39), fetal distress (29%; 95% CI, 0.08-0.49), preterm labor (23%; 95% CI, 0.14-0.32), and severe case or death (12%; 95% CI, 0.03-0.20). The subgroup analysis showed that compared with non-pregnant patients, pregnant women with COVID-19 had significantly lower incidences of fever (pregnant women, 51%; non-pregnant patients, 91%; P < 0.00001) and cough (pregnant women, 31%; non-pregnant patients, 67%; P < 0.0001). CONCLUSIONS: The incidences of fever, cough and positive CT findings in pregnant women with COVID-19 are less than those in the normal population with COVID-19, but the rate of preterm labor is higher among pregnant with COVID-19 than among normal pregnant women. There is currently no evidence that COVID-19 can spread through vertical transmission.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Obstetric Labor, Premature/epidemiology , Pneumonia, Viral/epidemiology , Pregnancy Complications, Infectious/epidemiology , COVID-19 , Cesarean Section , China/epidemiology , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/virology , Cough/epidemiology , Cough/virology , Female , Fever/epidemiology , Fever/virology , Humans , Incidence , Infant, Newborn , Infectious Disease Transmission, Vertical , Obstetric Labor, Premature/virology , Pandemics , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/virology , Pregnancy , Pregnancy Complications, Infectious/diagnostic imaging , Pregnancy Complications, Infectious/virology , Retrospective Studies , SARS-CoV-2 , Tomography, X-Ray Computed
18.
Chin. J. Microbiol. Immunol. ; 5(40): 336-343, 20200531.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-677732

ABSTRACT

Safe and effective vaccines are urgently needed to prevent and control the outbreak of COVID-19. 2019-nCoV belongs to the genus Betacoronavirus like severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Here we summarized the current progress and problems in the development of vaccines against SARS-CoV and MERS-CoV in order to provide reference for COVID-19 vaccine development.

19.
Build Simul ; : 1-11, 2020 Jun 26.
Article in English | MEDLINE | ID: covidwho-617377

ABSTRACT

Air curtains is promising in reducing the short-range infection risk in hospitals. To quantitatively evaluate its performance, this paper explores air curtains equipped on normal consulting desk to avoid doctor's direct exposure to the patient exhaled pollutants. A numerical investigation is conducted to evaluate the effects of supply air velocity and angle on cutting off performance. Simulation results show that the average mass fraction of exhaled pollutants decreases significantly (70%-90%) in the consulting ward, indicating satisfying performance of air curtains. Increasing supply air velocity is demonstrated to be conducive in forming full air curtains, whereas an excessively high supply air velocity may be of adverse effects by entraining exhaled flow. Besides, the supply air angle is also critical due to its coupling with supply air velocity. It is found that larger angle (0°-40°) is better where velocity is less than 3 m/s, otherwise a small angle (20°) is preferable where velocity is larger than 3 m/s. Exhaled flow could be well suppressed at the supply air angle 20° but moves over air curtains at 40°. This study can provide effective and intuitive guidance in applying air curtains in consulting wards. ELECTRONIC SUPPLEMENTARY MATERIAL ESM: supplementary material is available in the online version of this article at 10.1007/s12273-020-0649-7. The ESM files include the animation of patient exhaled droplets from the droplet birth at 0 s to 5 s under the supply air angle 0°, 20°, 40°, at supply air velocity 3 m/s.

SELECTION OF CITATIONS
SEARCH DETAIL